잠시만 기다려 주세요. 로딩중입니다.

Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication

Infection & Chemotherapy 2020년 52권 3호 p.396 ~ 402
홍경수, 장종걸, 허지안, 이종호, 김홍남, 이원화, 안준홍,
소속 상세정보
홍경수 ( Hong Kyung-Soo ) - Yeungnam University College of Medicine Department of Internal Medicine
장종걸 ( Jang Jong-Geol ) - Yeungnam University College of Medicine Department of Internal Medicine
허지안 ( Hur Ji-An ) - Yeungnam University College of Medicine Department of Internal Medicine
이종호 ( Lee Jong-Ho ) - Yeungnam University College of Medicine Department of Laboratory Medicine
김홍남 ( Kim Hong-Nam ) - Korea Institute of Science and Technology Brain Science Institute Center for BioMicrosystems
이원화 ( Lee Won-Hwa ) - Korea Research Institute of Bioscience and Biotechnology Aging Research Center
안준홍 ( Ahn June-Hong ) - Yeungnam University College of Medicine Department of Internal Medicine

Abstract


There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.

키워드

Early; Hydroxychloroquine; Coronavirus disease 2019; Eradication

원문 및 링크아웃 정보

등재저널 정보